Table 1.

The action under clinical development as of October 1st, 2021, for oncological indications; source, http://www.clinicaltrials.gov.

Mode of action	Condition	Progress	Status	Developer
β-glucan	Squamous Cell Carcinoma of the Oral Cavity	N/A	Active, not recntiting	Shih-Jung Cheng
Compound Vitamin Bl2	Nasopharyngeal Cancers	Phase II	N/A	WeiLUO
Fluvastatin sodium	Breast Cancer	Phase II	Completed	Laura J. Essennan
Migrat ion Inhibitory Factor (Anti-Mff) Antibody	Metastatic Adenocarcinoma of the Colon or Rectum	Phase I	Completed	Takeda
Pravastatin	Hepatocellular Carcinoma	Phase II	Terminated	Shehnaz Hussain
IDO1 Inhibitor	Oral Cavity Squamous Cell Carcinoma	Phase II	Recruiting	Adam Luginbuhl
β-glucan	Non Small Cell Lung Cancer	N/A	Recruiting	Goetz H Kloecker
Metfonnin Pioglitazone Hydrochloride	Oropharyngeal Neoplasm	Phase II	Terminated	Frank G Ondrey
Metfonnin Hydrochloride	Lung Carcinoma	Phase II	Not yet recruiting	Saikrishna S Yendamu ri
Estrogens/Bazedoxifene	Ductal Breast Carcinoma	Phase II	Recruiting	Swati Kulkarni

N/A, not applicable.